Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

MannKind Corporation (MNKD)

4.695   -0.125 (-2.59%) 12-05 13:06
Open: 4.81 Pre. Close: 4.82
High: 4.81 Low: 4.64
Volume: 1,047,024 Market Cap: 1,236(M)

Technical analysis

as of: 2022-12-05 12:50:57 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 5.65     One year: 6.6
Support: Support1: 3.91    Support2: 3.33
Resistance: Resistance1: 4.84    Resistance2: 5.65
Pivot: 4.43
Moving Average: MA(5): 4.65     MA(20): 4.32
MA(100): 3.72     MA(250): 3.74
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 90.9     %D(3): 92.9
RSI: RSI(14): 68.2
52-week: High: 4.86  Low: 2.49
Average Vol(K): 3-Month: 4,538 (K)  10-Days: 3,204 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MNKD ] has closed below upper band by 16.0%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.84 - 4.87 4.87 - 4.89
Low: 4.48 - 4.51 4.51 - 4.53
Close: 4.78 - 4.82 4.82 - 4.86

Company Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Headline News

Mon, 05 Dec 2022
MannKind's Return On Capital Employed Overview - MannKind (NASDAQ:MNKD) - Benzinga

Tue, 22 Nov 2022
MannKind Is Poised To Turn A Profit And Shares Could Get Cheaper (NASDAQ:MNKD) - Seeking Alpha

Mon, 21 Nov 2022
Should You Add MannKind Corp (MNKD) Stock to Your Portfolio Monday? - InvestorsObserver

Tue, 15 Nov 2022
Official: Mannkind worker hurt after equipment fire in Danbury - Danbury News Times

Thu, 10 Nov 2022
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting - GlobeNewswire

Wed, 09 Nov 2022
Is MannKind Corp (MNKD) a Stock to Watch After Gaining 16.52% This Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 263 (M)
Shares Float 259 (M)
% Held by Insiders 6.1 (%)
% Held by Institutions 50.3 (%)
Shares Short 35,040 (K)
Shares Short P.Month 35,330 (K)

Stock Financials

EPS -0.38
EPS Est Next Qtl -0.19
EPS Est This Year -0.92
EPS Est Next Year -0.76
Book Value (p.s.) -0.9
Profit Margin (%) -128
Operating Margin (%) -111.7
Return on Assets (ttm) -20
Return on Equity (ttm) 0
Qtrly Rev. Growth 47.7
Gross Profit (p.s.) 0.13
Sales Per Share 0.28
EBITDA (p.s.) -0.31
Qtrly Earnings Growth 0
Operating Cash Flow -91 (M)
Levered Free Cash Flow -86 (M)

Stock Valuations

PE Ratio -12.55
PEG Ratio -0.4
Price to Book value -5.23
Price to Sales 16.24
Price to Cash Flow -13.67

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-03-02
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.